A plaintiff in the 15-year-old litigation over Pfizer’s Fen-Phen diet drugs has lost his effort to obtain $776,000 in benefits from a settlement trust formed by Pfizer’s Wyeth wholly owned subsidiary.

The U.S. Food and Drug Administration in September 1997 ordered the drugs withdrawn from the market because of an association with heart valve disease.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]